Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone

Kobe Journal of Medical Sciences

Volumn 51, Issue 1, 2005, Pages 1-6

  Fujii, Hideki ^a,b   Nakahama, Hajime ^a   Yoshihara, Fumiki ^a   Nakamura, Satoko ^a   Inenaga, Takashi ^a   Kawano, Yuhei ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin receptor blocker; Candesartan; Hyperkalemia; Spironolactone

Indexed keywords

AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZOSEMIDE; CANDESARTAN HEXETIL; DOXAZOSIN MESYLATE; LOOP DIURETIC AGENT; METOPROLOL TARTRATE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; LABORATORY DIAGNOSIS; NEPHROSCLEROSIS; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; PROTEINURIA; RISK ASSESSMENT; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERKALEMIA; HYPERTENSION; MIDDLE AGED; NEPHROSCLEROSIS; SPIRONOLACTONE; TETRAZOLES;

EID: 24644520481     PISSN: 00232513     EISSN: 18830498     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Pitt B, Zannad F, Remme W et al. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717.
2. Chrysostomou A, and Becker G. 2001. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 345(12): 925-926.
3. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, and Ravid M. 2004. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 21(5):471-475
4. Zhou X, Ono H, Ono Y, and Frohlich ED. 2004. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol. 24(2):242-249
5. Schepkens H, Vanholder R, Billiouw JM, and Lameire N. 2001. Life-threatening hyperkalemia during combined therapy with angiotensin- converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med.110:438-441.
6. Mayan H, Kantor R, and Fartel Z. 2001. Trans-tubular potassium gradient in patients with drug-induced hyperkalemia. Nephron 89:56-61.
7. Halperin ML, and Kamel KS. 1998. Potassium. Lancet 352:135-140.
8. Take C, Ikeda K, Kurasawa T, and Kurokawa K. 1991. Increased chloride reabsorption as an inherited renal tubular defect in familial type II pseudohypoaldosteronism. N Engl J Med 354:472-476.
9. Reardon LC, and Macpherson DS. 1998. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. Arch Intern Med. 158:26-32.
10. Bakris GL, Siomos M, Richardson D, et al. 2000. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int 58:2084-2092.
11. Preston RA, Baltodano NM, Alonso AB, and Epstein M. 2002. Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus. J Clin Pharmacol 42:754-761.
12. Butler JV, McAvoy H, McEncroy D, and Mulkerrin EC. 2002. Spironolactone therapy in older patients - the impact of renal dysfunction. Arch Gerontol Geriatr. 35:45-49.
13. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, and Redelmeier DA. 2004. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 351(6):543-551.